Literature DB >> 20945502

Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line.

Calin O Marian1, Lin Yang, Ying S Zou, Crystal Gore, Rey-Chen Pong, Jerry W Shay, Wareef Kabbani, Jer-Tsong Hsieh, Ganesh V Raj.   

Abstract

BACKGROUND: The majority of established human prostate cancer cell lines are derived from metastatic lesions and are already tumorigenic in vivo, therefore immortalized normal prostate cell lines may provide a more relevant model to unveil the mechanisms associated with cancer progression and metastasis.
METHODS: PZ-HPV-7, an immortalized human prostate epithelial cell line was used to generate xenograft tumors in mice. A subline designated HPV-PZ-7T was subsequently derived from the subrenal capsule xenograft of a nude mouse. These cells were further characterized using karyotyping, immunofluorescence, qRT-PCR, Western blotting, and three-dimensional cultures in Matrigel.
RESULTS: The PZ-HPV-7 cell line possesses a typical epithelial morphology, expresses basal cell markers, and is capable of forming web-like structures with evidence of budding on Matrigel. PZ-HPV-7 is non-tumorigenic in immunocompromised mice by either subcutaneous injection or subrenal grafting. In contrast, the PZ-HPV-7T cells, derived from a xenograft tumor induced by co-inoculation with matrigel using subrenal grafting, possess a mesenchymal phenotype as well as luminal cell markers and are highly tumorigenic and metastatic in nude mice. Functionally and biochemically, the PZ-HPV-7T subline appears to have undergone an epithelial-to-mesenchymal transition (EMT) from the parental PZ-HPV-7 line.
CONCLUSION: We have developed a novel EMT model using an immortalized normal prostate epithelial cell line and generated a new prostate cancer cell line, PZ-HPV-7T, which may represent an excellent system to study mechanisms associated with prostate cancer progression and metastasis.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20945502     DOI: 10.1002/pros.21278

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process.

Authors:  Leonardo Freire-de-Lima; Kirill Gelfenbeyn; Yao Ding; Ulla Mandel; Henrik Clausen; Kazuko Handa; Sen-Itiroh Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

Review 2.  The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Authors:  Rhonda L Bitting; Daneen Schaeffer; Jason A Somarelli; Mariano A Garcia-Blanco; Andrew J Armstrong
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 3.  Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer.

Authors:  Arianna Bellazzo; Giulio Di Minin; Licio Collavin
Journal:  Cell Death Differ       Date:  2016-11-18       Impact factor: 15.828

4.  [From tumor tissue via primary cultures to xenograft models: a functional approach in prostate cancer research].

Authors:  M Saar; J Kamradt; V Jung; M Stöckle; G Unteregger
Journal:  Urologe A       Date:  2011-08       Impact factor: 0.639

5.  Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.

Authors:  Eun-Jin Yun; Jiancheng Zhou; Chun-Jung Lin; Elizabeth Hernandez; Ladan Fazli; Martin Gleave; Jer-Tsong Hsieh
Journal:  Clin Cancer Res       Date:  2015-10-21       Impact factor: 12.531

6.  Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis.

Authors:  Loukia N Lili; Lilya V Matyunina; L Deette Walker; Stephen L Wells; Benedict B Benigno; John F McDonald
Journal:  J Ovarian Res       Date:  2013-07-10       Impact factor: 4.234

7.  The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.

Authors:  Yuh-Shyan Tsai; Chen-Li Lai; Chih-Ho Lai; Kai-Hsiung Chang; Kaijie Wu; Shu-Fen Tseng; Ladan Fazli; Martin Gleave; Guanghua Xiao; Leah Gandee; Nima Sharifi; Loredana Moro; Tzong-Shin Tzai; Jer-Tsong Hsieh
Journal:  Oncotarget       Date:  2014-08-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.